Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077423 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Y-mAbs Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05077423: Clinical Trial Phase 1 study, sponsored by Y-mAbs Therapeutics.
NCT05077423 is a Phase 1 study that was terminated before completion, run by Y-mAbs Therapeutics. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05077423, a Phase 1 study, was terminated before completion, sponsored by Y-mAbs Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Pediatric patients (\<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33\*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
Primary Outcome
Occurrence of DLTs during a DLT period .
Interventions
- DRUG CD33*CD3 BsAb
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 1 |
Why NCT05077423 stopped before completion
NCT05077423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which CD33*CD3 BsAb is the first listed.
NCT05077423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05077423 about?
NCT05077423 is a clinical study titled "A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia". Pediatric patients (\<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33\*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
What is the current status of trial NCT05077423?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2022-05-25. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT05077423?
The interventions under investigation include: CD33*CD3 BsAb (DRUG).
Who is sponsoring clinical trial NCT05077423?
This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05077423's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI